Axogen Inc - AXGN STOCK NEWS

Axogen (NASDAQ: AXGN) has appointed Rick Ditto as Vice President of Global Health Economics, Reimbursement & Policy. Reporting to CEO Michael Dale, Ditto will spearhead coverage and reimbursement strategies to establish peripheral nerve function restoration as a standard of care.

Ditto brings over 15 years of medical device industry leadership experience from Zimmer Biomet, Johnson & Johnson, and Lumere. He holds degrees in Biomedical Engineering, Bioengineering, and Applied Health Economics & Outcomes Research.

As part of his employment package starting March 24, 2025, Ditto will receive an inducement grant on April 1, 2025, consisting of 45,000 Restricted Stock Units (RSUs) of Axogen common stock. The RSUs will vest over 4 years, with 50% vesting after two years and 25% vesting annually for the following two years.

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, has announced its upcoming Analyst & Investor Day scheduled for March 4, 2025, from 9am to 12pm Eastern time.

The event will feature presentations from key leadership including Chief Executive Officer Michael Dale, Chief Financial Officer Nir Naor, and other senior team members. Attendees can expect comprehensive insights into Axogen's business overview, strategic initiatives, growth plans, financial results, and future objectives.

For those unable to attend in person, a live webcast will be available on Axogen's investor relations website under "Axogen Virtual Analyst & Investor Day." A replay of the webcast will remain accessible for 90 days following the event.

Axogen reported its Q4 and full-year 2024 financial results. Q4 revenue was $49.4 million, a 15.1% increase from Q4 2023. The gross margin for Q4 was 76.1%, up from 74.6% in Q4 2023. Net income for Q4 was $0.4 million ($0.01 per share), compared to a net loss of $3.9 million ($0.09 per share) in Q4 2023. Adjusted net income for Q4 was $3.5 million ($0.07 per share), versus an adjusted net loss of $2.6 million ($0.06 per share) in Q4 2023. Adjusted EBITDA for Q4 was $6.7 million, up from $0.6 million in Q4 2023. Cash and equivalents stood at $39.5 million as of December 31, 2024.

For the full year, revenue was $187.3 million, a 17.8% increase from 2023. The full-year gross margin was 75.8%, slightly down from 76.6% in 2023. The net loss for the year was $10.0 million ($0.23 per share), compared to a net loss of $21.7 million ($0.51 per share) in 2023. Adjusted net income for the year was $5.9 million ($0.13 per share), versus an adjusted net loss of $7.3 million ($0.17 per share) in 2023. Adjusted EBITDA for the year was $19.8 million, compared to a loss of $1.1 million in 2023.

The FDA accepted Axogen's BLA for Avance® Nerve Graft, with a PDUFA date set for September 5, 2025. Axogen will hold an Investor Day on March 4, 2025, to discuss its 2025-2028 strategic plan. The company expects 2025 revenue growth of 15%-17% and gross margins of 73%-75%.

Axogen Inc (NASDAQ: AXGN), a global leader in surgical solutions for peripheral nerve injuries, has scheduled its 2024 fourth quarter and full year financial results announcement for Tuesday, February 25, 2025, before market opening. The company will host an investment-community conference call and webcast at 8 a.m. ET on the same day.

Investors can participate in the conference call by dialing (877) 407-0993 (toll-free) or (201) 689-8795 (direct). The webcast will be accessible through the Investors page on Axogen's website, where a replay will also be available after the call.

Axogen (NASDAQ: AXGN), a leader in surgical solutions for peripheral nerve injuries, has appointed Jesse Bishop as Vice President of Regulatory Affairs. Reporting to CEO Michael Dale, Bishop will lead domestic and international regulatory strategies for new product development, market approval, and regulatory initiatives.

Bishop brings over 13 years of leadership experience in regulatory strategy and CMC, CGMP manufacture of cell and gene therapies, having worked at companies including Thermo Fisher Scientific, RGI Medical Manufacturing, and Ology Bioservices. He served in the U.S. Army Special Operations as a Ranger Team Leader and Combat Medic and holds master's degrees in medical sciences and business administration from the University of Florida.

As part of his employment package starting February 3, 2025, Bishop will receive an inducement grant of 45,000 Restricted Stock Units (RSUs) on March 3, 2025. The RSUs will vest over 4 years, with 50% vesting after two years and 25% vesting annually for the following two years.

Axogen (NASDAQ: AXGN) has appointed Craig Swandal as Vice President of Operations, reporting to CEO Michael Dale. Swandal brings over 25 years of experience in medical device manufacturing leadership, including roles at Tendyne, Meier Tool and Engineering, ATS Medical, and Gyrus Medical.

As VP of Operations, Swandal will oversee manufacturing, supply chain, infrastructure strategies, tissue processing, distribution, purchasing, planning, manufacturing and process engineering, customer care, and continuous improvement.

As an inducement for employment, Swandal will receive an equity grant comprising 58,000 Restricted Stock Units (RSUs) vesting over 4 years and 58,000 Performance Stock Units (PSUs) tied to company stock price goals between February 2024 and February 2027. The PSUs can range from 0% to 200% based on achievement of specific stock price targets.

Axogen (NASDAQ: AXGN) announced preliminary unaudited revenue figures for Q4 and the full year 2024. The company expects fourth-quarter revenue of approximately $49.4 million, a 15.1% increase from Q4 2023. Full-year revenue is anticipated to be around $187.3 million, a 17.8% increase over 2023. This growth is attributed to improved execution of commercial strategies and increased adoption of Axogen's surgical solutions, particularly in Extremities and OMF-Head & Neck applications, as well as Resensation® for post-mastectomy breast reconstruction. Axogen projects a full-year gross margin above 75.5% and expects its cash, cash equivalents, and investments to total around $39.5 million by year-end, up $2.5 million from 2023. CEO Michael Dale expressed satisfaction with the company's performance and announced an Investor Day on March 4th, 2025, to share future strategic priorities. The results are preliminary and unaudited, with full audited results expected to be reported on or before Investor Day.

Axogen (NASDAQ: AXGN) reported Q3 2024 financial results with revenue of $48.6 million, up 17.9% year-over-year. Gross margin decreased to 74.9% from 76.8% in Q3 2023. Net loss improved to $1.9 million ($0.04 per share) compared to $4.1 million ($0.10 per share) last year. Adjusted EBITDA reached $6.5 million, up from $2.4 million in Q3 2023.

The FDA accepted the company's Biologics License Application for Avance Nerve Graft with a PDUFA date of September 5th, 2025. Axogen maintains full-year revenue guidance of $182-186 million and expects to be at the high end of its 74-76% gross margin range.

Axogen (NASDAQ: AXGN), a global leader in surgical solutions for peripheral nerve injuries, has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, before market opening. The company will host an investment-community conference call and webcast at 8 a.m. ET on the same day. Investors can participate via phone by dialing (877) 407-0993 (toll-free) or (201) 689-8795, or listen online through the Investors page at www.axogeninc.com. A replay will be available on the company's website after the call.